동종조혈모세포이식 환자에서 Tacrolimus와 Posaconazole 장용정 병용 시 Tacrolimus 용량 적절성 평가 = Evaluation of Tacrolimus Dosage during Co-administration of Posaconazole Enteric-coated Tablet in Allogenic Hematopoietic Stem Cell Transplantation

다국어 초록 (Multilingual Abstract)

Background : In allogenic hematopoietic stem-cell transplantation (HSCT), antifungal prophylaxis such as posaconazole is recommended to prevent invasive aspergillosis. However, blood concentration of tacrolimus is increased after taking it with posaconazole. The Ministry of Food and Drug Safety recommends the reduction of tacrolimus dose by one-third when receiving it with posaconzole. It was based on the study of posaconazole oral suspension. Thus, we evaluated the adequacy of tacrolimus dose adjustment when receiving it with posaconazole enteric-coated tablets in allogenic HSCT.
Methods : From January 2020 to December 2021, a single-center and retrospective study was conducted on patients who received tacrolimus and posaconazole enteric-coated tablets together for more than 5 days after allogenic HSCT. We investigated the mean blood concentration of tacrolimus before and after combination with posaconazole. Patients were divided into two groups: those with decreased tacrolimus dose by less than 60% and those with decreased tacrolimus dose by more than 60%. Interaction rate, rate of out of effective therapeutic range, and incidence of Graft-versus-host-disease (GVHD) and nephrotoxicity were evaluated for the two groups.
Results : Of 115 patients, the mean blood concentration of tacrolimus was significantly increased after receiving it with posaconazole (10.4 vs. 13.1 ng/mL, p < 0.0001). The interaction rate was significantly higher in the group of less than 60% reduction (37.9% vs. 19.3%, p=0.027). The rate of patients out of the effective therapeutic range was significantly different (37.2% vs. 25.5%, p = 0.018). The incidence of GVHD and nephrotoxicity were 68.7% and 71.3%, respectively.
Conclusion : Tacrolimus blood concentration was significantly increased when it was administered with posaconzole after allogenic HSCT. The interaction rate and the rate out of effective therapeutic range were significantly higher in the group of tacrolimus dose reduction by less than 60%. Thus, preemptive dose adjustment is required when tacrolimus and posaconazole enteric-coated tablets are used together in allogenic HSCT.

참고문헌 (Reference)

1 강형진, "조혈모세포이식의실제" 대한조혈모세포이식학회 2016

2 김보배 ; 김성환 ; 김귀숙 ; 이용화 ; 김향숙, "동종조혈모세포이식 시 Cyclosporine과Voriconazole 또는 Fluconazole의 약물상호작용 비교" 한국병원약사회 30 (30): 426-438, 2013

3 건강보험심사평가원, "고시 제 2022-131호 [일반원칙] 항진균제"

4 Pfizer-Korea, "Vfend®(voriconazole) prescribing information"

5 JM Morton, "Trough levels are inadequate for monitoring tacrolimus pharmacokinetics in lung transplantation" 21 (21): 144-, 2002

6 Dekkers BGJ, "Therapeutic Drug Monitoring of Posaconazole : an Update" 10 (10): 51-61, 2016

7 Collins J, "The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation" 26 (26): 5-12, 2020

8 Jung DS, "Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity" 58 (58): 6993-6995, 2014

9 Berge M, "Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis" 31 (31): 396-399, 2009

10 Przepiorka D, "Practical considerations in the use of tacrolimus for allogeneic marrow transplantation" 24 (24): 1053-1056, 1999

11 Gross BN, "Posaconazole Therapeutic Drug Monitoring in the Real-life Setting" 33 (33): 1117-1125, 2013

12 Sandherr M, "Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergilliosis – review of the literature" 16 (16): 139-144, 2011

13 Mikus G, "Pharmacogenomics of the triazole antifungal agent voriconazole" 12 (12): 861-872, 2011

14 MSD-Korea, "Noxafil®(posaconazole) prescribing information"

15 National Comprehensive Cancer Network, "NCCN Clinical Practice Guidelines in Oncology Prevention and Treatment of Cancer-Related Infections (NCCN Guidelines) Version1"

16 Arai S, "Management of graft-versus-host disease" 14 (14): 190-204, 2000

17 Saad AH, "Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants" 26 (26): 1730-1744, 2006

18 Sanchez-Ortega I, "Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients" 56 (56): 6422-6424, 2012

19 Groll AH, "Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4" 19 : e12751-, 2017

20 Gu TM, "Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations" 28 (28): 1357-1362, 2022

21 Venkataramanan R, "Clinical pharmacokinetics of tacrolimus" 29 (29): 404-430, 1995

22 Antiviral drugs advisory committee, F D A, "Briefing Document for Voriconazole(Oral and Intravenous Formulations)"

23 Segal BH, "Aspergillosis" 360 : 1870-1884, 2009

24 "2016 Guidelines, Practice Guidelines for the Diagnosis and Management of Aspergillosis:2016 Update"

25 "2010 ISDA guideline, Clinical practice guideline for the use antimicrobial agent in neutropenic patient with cancer: 2010update guideline"